Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.

Takeda Pharmaceutical's strong earnings, dividends, and strategic moves make it an appealing investment despite US policy ...

Q1 2025 Earnings Conference Call January 30, 2025 8:30 AM ETCompany ParticipantsJack Ezzell - CFOAustin Singleton ...

Q4 dividend income reached $2,118.56, reflecting smart investments in CNR, BEP.UN:CA, and ORCL. Learn why I trust dividend growth for long-term wealth.

For two years in a row, shares of our healthcare juggernaut UnitedHealth Group have lagged significantly. So, why are we ...

Driven by rapid innovations and the integration of modern technologies, the biotech sector is experiencing robust growth.

DeepSeek claims its R1 outperforms OpenAI’s latest o1 model despite costing a fraction of the price the U.S. AI lab charges ...

Analyst re-assesses Amazon stock ahead of Q4 2024 report, noting overvaluation and market-like returns expected.

United Rentals' recent acquisitions are expected to boost earnings power towards $45 per share. Click here to find out why I ...

Gain insights into Alibaba's financial performance, cloud revenue growth, and strategic positions for long-term investments ...

We recently published a list of 12 Cheap AI Stocks to Buy in 2025. In this article, we are going to take a look at where ...

XHB has outperformed the S&P 500 by 13 percentage points since my last buy rating, with shares up 58%, and I see more upside ...